# RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus

> **NCT04159974** · PHASE2 · UNKNOWN · sponsor: **University of Cologne** · enrollment: 56 (estimated)

## Conditions studied

- Esophageal Adenocarcinoma

## Interventions

- **DRUG:** Durvalumab 50 MG/ML
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT04159974
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-30
- **Primary completion:** 2024-06
- **Final completion:** 2024-06
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2024-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04159974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04159974, "RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04159974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*